- Home
- BTMD vs PYXS Comparison
BTMD vs PYXS Comparison
Compare BTMD & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTMD | PYXS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.4M | 71.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BTMD | PYXS |
|---|---|---|
| Price | $2.19 | $1.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.00 | ★ $6.75 |
| AVG Volume (30 Days) | 164.4K | ★ 1.2M |
| Earning Date | 03-11-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 270.48 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $195,645,000.00 | $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.37 | N/A |
| P/E Ratio | $2.88 | ★ N/A |
| Revenue Growth | ★ 1.34 | N/A |
| 52 Week Low | $2.03 | $0.83 |
| 52 Week High | $5.03 | $5.55 |
Technical Indicators
Market Signals| Indicator | BTMD | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 36.12 |
| Support Level | $2.08 | $1.38 |
| Resistance Level | $2.29 | $1.69 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 41.18 | 10.69 |
Price Performance
Historical ComparisonAbout BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.